Programm                 "Degeneration und Regeneration– Grundlagen, Diagnostik und Therapie"


Hotelbuchung
   Hotel Registration
Grußwort
   Welcome address
Beteiligte Gesellschaften
   Societies involved
DOG Information
   DOG Information
Eröffnung des Kongresses
   Opening Ceremony
Preise
   Awards
Ablauf der Tagung 2003
   General overview of congress
Lageplan der Räumlichkeiten
   Map of Congress Center
Wissenschaftliche Themen
   Scientific topics
Symposien
   Symposia
Wissenschaftliches Programm
   Scientific program
Posterpräsentationen
   Poster Presentation
Kurse
   Courses
Begleitende Veranstaltungen
   Accompanying program
Arbeitssitzungen
   Working sessions
Rahmenprogramm
   Social program
Allgemeine Informationen
   General Information
Autorenindex
   Index of Authors
Industrieaussteller
   Commercial exhibitors
Sponsoren
   Sponsors
Impressum



DOG Homepage


Abstract
Abstract

ILM Peeling versus Triamcinolone in Persistent Diabetic Macular Edema (TIME-Study)

Joussen A. M.1, Kirchhof B.1, Wolf S.2, Hilgers R.-D.3
1Universität zu Köln, Zentrum für Augenheilkunde, Abteilung für Netzhaut- und Glaskörperchirurgie, Köln; 2Universität Leipzig, Klinik und Poliklinik für Augenheilkunde, Leipzig; 3RWTH Aachen, Institut für Medizinische Statistik, Aachen

Aim: Improvement of the visual outcome for patients with persistent diabetic macular edema
Study Design: Three arm parallel group design: two treatment groups, and one control group
Patients: Patients with persistent macular edema (as a consequence of diabetic maculopathy)
Time of the Study: 4 years
Treatment:
· Group 1: control: no treatment
· Group 2: ppV and posterior vitreous detachment + ILM peeling
· Group 3: triamcinolone 4 mg (6 monthly (optional))
Inclusion Criteria:
· Persistent (diffuse or focal) macular edema (more than 6 month) as demonstrated by fluorescein angiography according to ETDRS criteria for CSME associated with diabetes
· BCVA of the treatment eye £20/50 +3 £ETDRS letters) and ³20/320 (³25 ETDRS letters). Fellow eye ³20/100 (25 ETDRS letters)
· Last focal or grid laser treatment for macular edema more than 3 month prior to treatment
· Type II diabetes

Zurück | Back